0000950170-24-064309.txt : 20240524 0000950170-24-064309.hdr.sgml : 20240524 20240524081517 ACCESSION NUMBER: 0000950170-24-064309 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20240524 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240524 DATE AS OF CHANGE: 20240524 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CG Oncology, Inc. CENTRAL INDEX KEY: 0001991792 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 371611499 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-41925 FILM NUMBER: 24980887 BUSINESS ADDRESS: STREET 1: 400 SPECTRUM CENTER DRIVE STREET 2: SUITE 2040 CITY: IRVINE STATE: CA ZIP: 92618 BUSINESS PHONE: (949) 419-6203 MAIL ADDRESS: STREET 1: 400 SPECTRUM CENTER DRIVE STREET 2: SUITE 2040 CITY: IRVINE STATE: CA ZIP: 92618 8-K 1 ck0001991792-20240524.htm 8-K 8-K
false000199179200019917922024-05-242024-05-24

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 24, 2024

 

 

CG Oncology, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-41925

37-1611499

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

400 Spectrum Center Drive

Suite 2040

 

Irvine, California

 

92618

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: (949) 409-3700

 

N/A

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, par value $0.0001 per share

 

CGON

 

The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

Item 7.01 Regulation FD Disclosure.

 

On May 24, 2024, CG Oncology, Inc. (the “Company”) issued a press release entitled “CG Oncology to Present Positive Final Results from Phase 2 CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive High-Risk NMIBC at ASCO 2024 Annual Meeting.” The full text of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.

 

On May 24, 2024, the Company posted an updated corporate presentation on the Company’s website. Investors may access the presentation by visiting the “Investor Relations” section of the Company’s website at www.cgoncology.com. The Company plans to use its website to disseminate future updates to its corporate presentation and does not intend to file or furnish a Form 8-K alerting investors each time the presentation is updated.

 

The information furnished under this Item 7.01 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section. The information shall not be deemed incorporated by reference into any other filing with the Securities and Exchange Commission made by the Company, regardless of any general incorporation language in such filing.

 

By furnishing the information in this Item 7.01, the Company makes no admission as to the materiality of Item 7.01 in this report or the presentation available on the Company’s website. The information contained in the corporate presentation is summary information that is intended to be considered in the context of the Company’s filings with the Securities and Exchange Commission and other public announcements that the Company makes, by press release or otherwise, from time to time. The Company undertakes no duty or obligation to publicly update or revise the information contained in this Item 7.01, although it may do so from time to time as its management believes is appropriate or as required by applicable law. Any such updating may be made through the filing of other reports or documents with the Securities and Exchange Commission, through press releases, by updating its website or through other public disclosure.

 

Item 8.01 Other Events.

 

On May 24, 2024, the Company announced final results from the Phase 2 CORE-001 clinical trial of its oncolytic immunotherapy candidate, cretostimogene, in combination with pembrolizumab for the treatment of BCG-Unresponsive, High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) with Carcinoma in Situ (CIS). The data will be presented at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting, held May 31-June 4, in Chicago, IL.

 

CORE-001 final results:

 

•
As of the data cutoff on February 5, 2024, the complete response (CR) rate in the intention-to-treat (ITT) population at 12-months and any time, was 57% (20/35) [95% confidence interval (CI), 40-73%] and 83% (29/35) (95% CI, 70-95%), respectively. As of May 17, 2024, the CR rate in the ITT population at 24 months was 54% (19/35) (95% CI, 37-71%).
•
Of the patients in a CR at 12 months, 95% of patients (19/20) maintained a CR for another 12 months.
•
Median duration of response (DoR) has not been reached but exceeds 21 months.
•
Additionally, the Kaplan-Meier estimates for CR rate at 12 and 24 months were 77.3% (95% CI, 58.1-88.5%) and 69.6% (95% CI, 49.4-83.0%), respectively.
•
Progression-free survival (PFS) at 24 months is 100% with no patients progressing to muscle invasive cancer or metastatic disease; Cystectomy-free survival (CFS) at 24 months was 80%; for patients in CR, CFS at 24 months was 100%.
•
Treatment-related adverse events (TRAEs) were consistent with the individual agents and demonstrate no synergistic toxicity. Results to be presented are an update from previously reported data in the abstract.

 

CORE-001 is a Phase 2 single-arm, open-label clinical trial of cretostimogene administered in 35 patients with high-risk, BCG-Unresponsive NMIBC that have CIS, in combination with pembrolizumab, following disease resection. CORE-001 was conducted pursuant to a clinical collaboration and supply agreement with Merck (known as MSD outside the United States and Canada).

 

Additionally, the Company believes these results support further investigation of cretostimogene in combination with checkpoint inhibitors and it plans to incorporate these findings into its planned CORE-008 trial in high-risk NMIBC.

 

Forward Looking Statements

 

The Company cautions you that statements contained in this report regarding matters that are not historical facts are forward-looking statements. The forward-looking statements are based on our current beliefs and expectations and include, but are not limited to: the potential therapeutic benefits of cretostimogene in combination with pembrolizumab for high-risk NMIBC patients and the importance of the data as they relate to addressing bladder cancer. Actual results may differ from those set forth in this report due to the risks and uncertainties inherent in our business, including, without limitation: reported topline data is based on preliminary analysis of key efficacy and safety data is subject to more audit and verification procedures that could result in material changes in the final data; additional patient data related to cretostimogene in combination with pembrolizumab that continues to become available may be inconsistent with the data produced as of the date hereof, and further analysis of existing data and analysis of new data may lead to conclusions different from those established as of the date hereof; results from earlier clinical trials and preclinical studies not necessarily being predictive of future results; unexpected adverse side effects or inadequate efficacy of cretostimogene that may limit its development, regulatory approval, and/or commercialization; and other risks described in our filings with the Securities and Exchange Commission (SEC), including under the heading “Risk Factors” in our annual report on Form 10-K and any subsequent filings with the SEC (which are available at http://www.sec.gov). You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and we undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

 

 

Item 9.01 Financial Statements and Exhibits.

(d)

Exhibits

 

 

 

Exhibit No.

Description

 

 

99.1

Press release, dated May 24, 2024.

104

 

Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

CG Oncology, Inc.

 

 

Date: May 24, 2024

By: /s/ Josh Patterson

 

Name: Josh Patterson

 

Title: General Counsel and Chief Compliance Officer

 

 

 EX-99.1 2 ck0001991792-ex99_1.htm EX-99.1 EX-99.1

 

Exhibit 99.1

img89521117_0.jpg 

CG Oncology to Present Positive Final Results from Phase 2 CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive High-Risk NMIBC at ASCO 2024 Annual Meeting

 

– 54% complete response (CR) rate at 24-month landmark and meets primary endpoint of the phase 2 study –

 

IRVINE, Calif., May 24, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced final results from the Phase 2 CORE-001 clinical trial of its oncolytic immunotherapy candidate, cretostimogene, in combination with pembrolizumab for the treatment of BCG-Unresponsive, High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) with Carcinoma in Situ (CIS). The data will be presented at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting from May 31-June 4, in Chicago, IL.

 

“There is a significant unmet need for new and innovative treatments for patients suffering with bladder cancer. We are encouraged by the final safety and efficacy data from our CORE-001 Phase 2 trial which showed a class-leading complete response (CR) and duration of response (DoR) compared to existing FDA-approved therapies and other investigational candidates,” said Vijay Kasturi, MD, Chief Medical Officer, CG Oncology. “We look forward to sharing these data at ASCO, as they reinforce the potential use of cretostimogene as a bladder-sparing backbone therapy for NMIBC, which is generally well tolerated by patients, either as monotherapy or in combination. Additionally, we believe these results support further investigation of cretostimogene in combination with checkpoint inhibitors and we plan to incorporate these findings into our planned CORE-008 trial in high-risk NMIBC.”

 

 

 

 

CORE-001 Final Results:

•
As of the data cutoff on February 5, 2024, the CR rate in the intention-to-treat (ITT) population at 12-months and any time, was 57% (20/35) [95% confidence interval (CI), 40-73%] and 83% (29/35) (95% CI, 70-95%), respectively. As of May 17, 2024, the CR rate in the ITT population at 24 months was 54% (19/35) (95% CI, 37-71%).
•
Of the patients in a CR at 12 months, 95% of patients (19/20) maintained a CR for another 12 months.
•
Median DoR has not been reached but exceeds 21 months.
•
Additionally, the Kaplan-Meier estimates for CR rate at 12 and 24 months were 77.3% (95% CI, 58.1-88.5%) and 69.6% (95% CI, 49.4-83.0%), respectively.
•
Progression-free survival (PFS) at 24 months is 100% with no patients progressing to muscle invasive cancer or metastatic disease; Cystectomy-free survival (CFS) at 24 months was 80%; for patients in CR, CFS at 24 months was 100%.
•
Treatment-related adverse events (TRAEs) were consistent with the individual agents and demonstrate no synergistic toxicity. Results to be presented are an update from previously reported data in the abstract.

 

Details of the ASCO poster are as follows:

Title: Final results of CORE-001 trial of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in Patients with BCG-Unresponsive, High-Risk, Non-Muscle Invasive Bladder Cancer with Carcinoma in Situ

Abstract Number: 4601

Session & Primary Track: Poster Session, Genitourinary Cancer - Kidney and Bladder

Presenter: Roger Li, M.D., lead study investigator and Urologic Oncologist at Moffitt Cancer Center

Presentation Date & Time: June 2, 2024, 9:00-10:00am Central Daylight Time

Location: McCormick Place Convention Center, Hall A

 

 

 

 

The Phase 2 CORE-001 trial was conducted in collaboration with Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. The combination of cretostimogene and pembrolizumab received FDA Breakthrough Therapy Designation in May 2023.

 

Cretostimogene monotherapy received FDA Fast Track and Breakthrough Therapy Designations in BCG-Unresponsive, HR-NMIBC with CIS in December 2023. CG Oncology recently presented data from the Phase 3 BOND-003 trial at the 2024 American Urological Association Annual Meeting which showed sustained durable responses over 12 months and a 75.2% complete response rate. Topline data from BOND-003 is expected by the end of 2024, and the Company is on track for a regulatory approval submission. To learn more about the results from BOND-003 you may read the Company’s press release issued on May 3, 2024.

 

About Cretostimogene Grenadenorepvec

Cretostimogene is an investigational, intravesically delivered oncolytic immunotherapy being evaluated in BOND-003, a Phase 3 clinical trial for the treatment of patients with high-risk Non-Muscle Invasive Bladder Cancer (NMIBC) who are unresponsive to Bacillus Calmette Guerin (BCG) therapy. Cretostimogene is also being evaluated in a Phase 3 monotherapy clinical trial (PIVOT-006) in intermediate-risk NMIBC patients. In addition, cretostimogene is being evaluated in an investigator-sponsored clinical trial in combination with nivolumab for the treatment of muscle invasive bladder cancer.

 

Cretostimogene is an investigational, intravesically delivered oncolytic immunotherapy candidate, and its safety and efficacy have not been established by the FDA or any other health authority.

 

 

 

 

About the CORE-001 Study

CORE-001 was a Phase 2 single-arm, open-label clinical trial of cretostimogene administered in 35 patients with high-risk, BCG-Unresponsive NMIBC that have carcinoma in situ-containing tumors, in combination with pembrolizumab, following disease resection. CORE-001 was conducted pursuant to a clinical collaboration and supply agreement with Merck (known as MSD outside the United States and Canada). More information about the study, CORE-001 (NCT04387461), along with other studies sponsored by CG Oncology, can be found at www.clinicaltrials.gov or www.cgoncology.com.

 

About CG Oncology

CG Oncology is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. CG Oncology sees a world where urologic cancer patients may benefit from our innovative immunotherapies to live with dignity and have an enhanced quality of life. To learn more, please visit: www.cgoncology.com.

 

 

 

 

Forward Looking Statements

CG Oncology cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. The forward-looking statements are based on our current beliefs and expectations and include, but are not limited to, the potential therapeutic benefits of cretostimogene in combination with pembrolizumab for high-risk NMIBC patients and the importance of the data as they relate to addressing bladder cancer and supporting further investigation in combination with checkpoint inhibitors; the anticipated timing of BOND-003 final data; and the Company’s expectations on a regulatory approval submission. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in our business, including, without limitation: additional patient data related to cretostimogene in combination with pembrolizumab that continues to become available may be inconsistent with the data produced as of the data cutoff, and further analysis of existing data and analysis of new data may lead to conclusions different from those established as of the date hereof; results from earlier clinical trials and preclinical studies not necessarily being predictive of future results; unexpected adverse side effects or inadequate efficacy of cretostimogene that may limit its development, regulatory approval, and/or commercialization; potential delays in the commencement, enrollment and completion of clinical trials; and other risks described in our filings with the Securities and Exchange Commission (SEC), including under the heading “Risk Factors” in our annual report on Form 10-K and other filings that we make with the SEC from time to time (which are available at http://www.sec.gov). You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and we undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

 

 

 

 

Contacts:

Media

Sarah Connors

(508) 654-2277

media@cgoncology.com

 

Investor Relations

Laurence Watts

New Street Investor Relations LLC

(619) 916-7620

IR@cgoncology.com

 

 

 

 GRAPHIC 3 img89521117_0.jpg GRAPHIC begin 644 img89521117_0.jpg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ck0001991792-20240524.xsd XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 100000 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink Cover [Abstract] Amendment Flag City Area Code Document Period End Date Document Type Entity Address, Address Line One Entity Address, Address Line Two Entity Address, City or Town Entity Address, Postal Zip Code Entity Address, State or Province Entity Central Index Key Entity Emerging Growth Company Entity Ex Transition Period Entity File Number Entity Incorporation, State or Country Code Entity Information, Former Legal or Registered Name Entity Registrant Name Entity Tax Identification Number Local Phone Number Pre-commencement Issuer Tender Offer Pre-commencement Tender Offer Title of 12(b) Security Security Exchange Name Soliciting Material Trading Symbol Written Communications XML 6 R1.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Document And Entity Information
May 24, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date May 24, 2024
Entity Registrant Name CG Oncology, Inc.
Entity Central Index Key 0001991792
Entity Emerging Growth Company true
Entity File Number 001-41925
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 37-1611499
Entity Address, Address Line One 400 Spectrum Center Drive
Entity Address, Address Line Two Suite 2040
Entity Address, City or Town Irvine
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92618
City Area Code (949)
Local Phone Number 409-3700
Entity Information, Former Legal or Registered Name N/A
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Ex Transition Period false
Title of 12(b) Security Common Stock, par value $0.0001 per share
Trading Symbol CGON
Security Exchange Name NASDAQ

EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.1.u2 html 1 25 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document And Entity Information Sheet http://cgoncology.com/20240524/taxonomy/role/DocumentDocumentAndEntityInformation Document And Entity Information Cover 1 false false All Reports Book All Reports ck0001991792-20240524.htm ck0001991792-20240524.xsd http://xbrl.sec.gov/dei/2024 false false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "ck0001991792-20240524.htm": { "nsprefix": "ck0001991792", "nsuri": "http://cgoncology.com/20240524", "dts": { "inline": { "local": [ "ck0001991792-20240524.htm" ] }, "schema": { "local": [ "ck0001991792-20240524.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" ] } }, "keyStandard": 25, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2024": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 26, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2024": 25 }, "report": { "R1": { "role": "http://cgoncology.com/20240524/taxonomy/role/DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document And Entity Information", "shortName": "Document And Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "C_7a771ff1-2a30-4bda-ae80-8846cb6d8a8b", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "ck0001991792-20240524.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_7a771ff1-2a30-4bda-ae80-8846cb6d8a8b", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "ck0001991792-20240524.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://cgoncology.com/20240524/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [ "http://cgoncology.com/20240524/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://cgoncology.com/20240524/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://cgoncology.com/20240524/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://cgoncology.com/20240524/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": [ "http://cgoncology.com/20240524/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://cgoncology.com/20240524/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://cgoncology.com/20240524/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://cgoncology.com/20240524/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://cgoncology.com/20240524/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://cgoncology.com/20240524/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityExTransitionPeriod", "presentation": [ "http://cgoncology.com/20240524/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r7" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://cgoncology.com/20240524/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://cgoncology.com/20240524/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInformationFormerLegalOrRegisteredName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInformationFormerLegalOrRegisteredName", "presentation": [ "http://cgoncology.com/20240524/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Information, Former Legal or Registered Name", "documentation": "Former Legal or Registered Name of an entity" } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://cgoncology.com/20240524/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://cgoncology.com/20240524/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://cgoncology.com/20240524/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://cgoncology.com/20240524/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementTenderOffer", "presentation": [ "http://cgoncology.com/20240524/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [ "http://cgoncology.com/20240524/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [ "http://cgoncology.com/20240524/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SolicitingMaterial", "presentation": [ "http://cgoncology.com/20240524/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://cgoncology.com/20240524/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "WrittenCommunications", "presentation": [ "http://cgoncology.com/20240524/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14a", "Subsection": "12" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 14 0000950170-24-064309-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-24-064309-xbrl.zip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end XML 16 ck0001991792-20240524_htm.xml IDEA: XBRL DOCUMENT 0001991792 2024-05-24 2024-05-24 false 0001991792 8-K 2024-05-24 CG Oncology, Inc. DE 001-41925 37-1611499 400 Spectrum Center Drive Suite 2040 Irvine CA 92618 (949) 409-3700 N/A false false false false Common Stock, par value $0.0001 per share CGON NASDAQ true false